Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection [Phase 3]

View source ↗

Summary

Phase 3 clinical trial completed evaluating ABT-493/ABT-530 in Japanese adults with genotype 2 chronic hepatitis C virus infection; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C Virus, Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2019-02-15